Company Analysis: Incyte

Company Analysis: Incyte

  • January 2021 •
  • 56 pages •
  • Report ID: 6102721 •
  • Format: PDF
PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.

Overview – Incyte continues to be driven by robust Jakafi sales.
Key themes – [1] Incyte continues to grow Jakafi volumes at a strong pace, with supplemental approvals and label expansions adding to the lifecycle management of the drug [2] Jakafi patent expiration in 2028 is a key event for Incyte as the drug will comprise a significant proportion of company revenues [3] Royalties and collaboration revenues will substantially bolster Incyte over the forecast period.

Model updates (6 November 2020)

Pemazyre forecast adjusted higher due to launch trend.

Model updates (4 August 2020)

Tafasitamab name changed to Monjuvi following US July approval
Itacitinib forecast pushed back due to treatment-naïve acute GVHD trial results
Jakafi forecast adjusted lower due to COVID-19 impact
Pemazyre 5EU and RoW forecast added due to pending EU approval decision.

Model updates (5 May 2020)

Jakafi forecast adjusted higher due to continued uptake in GVHD
Pemigatinib name changed to Pemazyre; forecast pulled forward due to earlier-than-anticipated approval for cholangiocarcinoma
Tafasitamab forecast added due to closing of licensing agreement with MorphoSys.

Model updates (13 February 2020)

Jakafi forecast adjusted higher due to continued growth in MF, strong growth in PV, and an above-expectations launch in steroid-refractory acute GVHD.